Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06413537 · ClinicalTrials.gov registry record · Phase 2
Study of SPG601 in Adult Men With Fragile X Syndrome
A Phase 2 study, sponsored by Spinogenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT06413537 is a Phase 2 study that has completed, run by Spinogenix. The registered enrollment target is 10 participants.
The verdict
NCT06413537, a Phase 2 study, has completed, sponsored by Spinogenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
Interventions
- DRUG Placebo
- DRUG SPG601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06413537
The ClinicalTrials.gov registry entry for NCT06413537 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spinogenix, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06413537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06413537 about?
NCT06413537 is a clinical study titled "Study of SPG601 in Adult Men With Fragile X Syndrome". This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
What is the current status of trial NCT06413537?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2024-07-05. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT06413537?
The interventions under investigation include: Placebo (DRUG), SPG601 (DRUG).
Who is sponsoring clinical trial NCT06413537?
This trial is sponsored by Spinogenix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.